Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Core Insights - Chimerix, a biopharmaceutical company, focuses on developing medicines to improve and extend the lives of patients with deadly diseases [1][3] - The CEO, Mike Andriole, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024 [1] - The company's leading clinical-stage program, ONC201, targets H3 K27M-mutant glioma [3] Company Information - Chimerix is dedicated to creating impactful treatments for patients facing severe health challenges [3] - The company has a significant focus on advancing its clinical-stage development programs [3]